tradingkey.logo

Johnson & Johnson's Tar-200 Monotherapy Demonstrates Highest Complete Response Rate With Sustained Clinical Benefits In Patients With Certain Types Of Bladder Cancer

ReutersApr 26, 2025 6:01 PM

- Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON'S TAR-200 MONOTHERAPY DEMONSTRATES HIGHEST COMPLETE RESPONSE RATE WITH SUSTAINED CLINICAL BENEFITS IN PATIENTS WITH CERTAIN TYPES OF BLADDER CANCER

  • JOHNSON & JOHNSON - PHASE 2B STUDY: 82% ACHIEVE COMPLETE RESPONSE, 52.9% CANCER-FREE AT ONE YEAR

  • JOHNSON & JOHNSON - TAR-200 POTENTIAL TO TRANSFORM OUTCOMES FOR BCG-UNRESPONSIVE BLADDER CANCER

  • JOHNSON & JOHNSON - INITIATES FDA APPLICATION FOR TAR-200 UNDER RTOR PROGRAM

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI